Introduction Interferon
Progress has been made over the past 5 years toward the development of specific biological approaches to the treatment of cancer. The techniques of genetic engineering and mass cell culture, and improved techniques in protein and nucleic acid sequencing, have made available biologics as highly purified molecules. The most definitive investigations have been carried out with natural and cloned interferon-c~ preparations, and it is clear that they are capable of inducing responses primarily in patients with certain types of lymphomas and leukemias. Interferons are a family of proteins produced by cells in response to virus, double-stranded ribonucleic acid, antigens, and mitogens (1) . In addition to antiviral activity (2), the interferons have profound effects on a number of components of the immune system, including B, T, and natural killer cells and macrophages (3, 4) , and have antiproliferative activity (4, 5) . With respect to the interferons and cancer therapy, it is still unclear whether the interferons work primarily by their antiproliferative activity or through alterations of immune responses. It is clear, however, from both preclinical and clinical studies that interferons have antitumor activity in a number of tumor systems (6, 7) .
Leukernias and lymphomas
The most extensively studied interferons clinically are the natural and recombinant interferon-c~ preparations. At the National Cancer Institute we recently completed a phase II interferon trial for previously treated patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and cutaneous T cell lymphoma (mycosis fungoides). We chose these diseases because earlier trials with natural interferon-a preparations suggested they would be responsive (8) (9) (10) . Patients were treated with highly purified recombinant leukocyte A interferon (Hoffmann-La Roche, Nutley, New Jersey) at 50 × 106 U/m 2 body surface area three times weekly by the intramuscular route; the dose and schedule were based on the maximum tolerated dose from our phase I study (11). Patients were treated for three months, and dose reductions to 50% and then 10% of the starting dose were made based on unacceptable toxicity (e.g., fatigue, anorexia, leukopenia, elevated hepatic transaminases). Eighty-four patients were entered on our phase II lymphoma/leukemia trial. Forty-five of these patients had non-Hodgkin's lymphoma (12), 20 had cutaneous T cell lymphoma (13) , and 19 had chronic lymphocytic leukemia (14) . Major toxic reactions observed were fever, chills, fatigue, and anorexia. The average duration of therapy was 2.5 weeks at the 100% dose and 6.5 weeks at the 50% dose. Fatigue was the most common reason for dose reduction.
Our results indicated significant antitumor activity for recombinant leukocyte A interferon in patients with low grade and intermediate grade histology non-Hodgkin's lymphoma classified by the Working Formulation (15) , and for patients with cutaneous T cell lymphoma (Table 1) . Fiftyfive percent of the patients with low grade and intermediate grade histology non-Hodgkin's lymphoma and nearly 50% with cutaneous T cell lymphoma responded with either partial or complete responses, All responding patients were maintained on recombinant leukocyte A interferon therapy; the median duration of response was 8 months for non-Hodgkin's lymphoma and 6 months for cutaneous T cell lymphoma. The five complete responders with low grade and intermediate grade histology non-Hodgkin's lymphoma were shown to be tumor free in sites of previous disease by noninvasive studies and biopsies where indicated. Responses included resolution of bone marrow disease as well as bulky disease in the mediastinum and retroperitoneum (12, 16) . The responses in patients with cutaneous T cell lymphoma included reductions of the size of skin plaques and tumors, lymph nodes, and circulating Sdzary cells. It was particularly interesting that all of the responding patients had very advanced disease and had failed multiple courses of combination chemotherapy. Recombinant leukocyte A interferon was not effective in this dose schedule for patients with advanced chronic lymphocytic leukemia, with only 2 partial responses and 11 of 18 evaluable patients progressing while on interferon therapy (14) . We began a phase II trial of recombinant leukocyte A interferon for advanced hairy cell leukemia patients based on the reported excellent results using natural interferon-c~ (17) . Twenty patients were treated with intramuscular and/or subcutaneous injections of recombinant leukocyte A interferon at 3 x 106 U daily and 14 have completed at least 12 weeks of treatment and are evaluable for response (18) . There was one complete response and 12 partial responses for an overall response rate of 93%. All of the partial responders have had a substantial improvement in their hematologic parameters and at a median follow-up of six months not a single patient has relapsed or become refractory to interferon. While only one patient has thus far demonstrated disappearance of bone marrow disease, it does not appear that the absence of hairy cells in the bone marrow is necessary for an optimal clinical response. The only major toxicity was transient myelosuppression during the first week of therapy. Immunologic studies have demonstrated improvement in natural killer activity and lymphoid subpopulations, both coincident with normalization of the hematologic parameters.
Chronic myelogenous leukemia also appears to be responsive to interferon-a, with hematologic remission reported in 5 of 7 patients treated (19) . These patients had improved hematologic parameters as well as reduction in the size of enlarged spleens and were maintained on 3 × 1@ U of interferon-a daily or every other day.
Our phase II studies have demonstrated that recombinant leukocyte A interferon has the highest reported response rate for any standard or experimental agent in advanced previously treated cutaneous T cell lymphoma patients. It also establishes recombinant leukocyte A interferon as a new non-cross-resistant modality of therapy for low grade and intermediate grade histology nonHodgkin's lymphoma. We have also confirmed earlier reports that interferon-a is the most active single agent for hairy cell leukemia and should be considered for therapy when splenectomy is no longer effective in controlling the disease. Finally, interferon-a has activity in chronic myelogenous leukemia. Phase III trials for previously untreated patients with non-Hodgkin's lymphoma, cutane-
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ous T cell lymphoma,:,hairy cell leukemia, and chronic myelogenous leukemia patients are clear avenues of future investigation.
Solid tumors
Antitumor activity for the alpha interferons has been quite limited for solid tumors. The greatest solid tumor activity has been described for Kabosi's sarcoma with approximately a 50% response rate (20, 21) . Results for breast cancer have been mixed, with some responses reported with rather crude Cantell preparations and recombinant preparations of interferon alpha (10, 22, 23) and interferon beta (24) . However, there is also conflicting data suggesting no responses for breast cancer patients treated with recombinant preparations of interferon alpha (25) (26) (27) . Renal cell carcinoma is among the most unresponsiv e tumors to any known cytotoxic agents, and approximately a 15% partial response rate for interferon alpha has been reported for patients with renal cell carcinoma. These results have been reported for crude interferon preparations (28) and cloned agents (29, 30) . Melanoma is another tumor that has no standard effective chemotherapy; partial response rates of approximately 20 percent have been reported for interferon alpha (31, 32) . Responses for other common solid tumors such as bronchogenic carcinoma (33, 34) and colon cancer (35, 36) have been negative. Preliminary trials with crude alpha interferon preparations from Yugoslavia suggested some activity for head and neck cancers (37, 38) ; however, these results have not been confirmed in the United States.
Monoelonal antibodies

Treatment trials
Clinical trials with monoclonal antibodies in humans have been designed to approach preliminary questions with respect to the feasibility and toxicity of monoclonal antibody therapy and the rationale for the use of these reagents (39-56) ( Table 2) . While most of these trials have involved single Forty patients with B cell derived chronic lymphocytic leukemia and cutaneous T cell lymphoma have been treated with the T101 or the anti-Leu-1 antibodies, which recognize a 65 to 69,000 molecular weight glycoprotein antigen (39) (40) (41) (42) (45) (46) (47) (48) . Patients in these studies have been treated with 1-12 dosages ranging from 7 to 1000mg (single doses ranging from I to 150 rag). Transient reductions in circulating leukemia cell counts were described in most of these patients; however, they were rarely sustained beyond 24 to 48 hours after the completion of therapy. A number of patients with cutaneous T cell lymphoma demonstrated transient reductions in the size of cutaneous skin lesions and enlarged lymph nodes. In these studies, in vivo antibody localization to tumor cells in the peripheral blood, bone marrow, lymph nodes, and cutaneous lesions was identified.
Four patients with acute lymphoblastic leukemia were treated with escalating doses of the J5 monoclonal antibody, which binds to the common acute lymphoblastic leukemia antigen (CALLA) (52) . In this study, patients demonstrated transient reductions in the circulating leukemia cells immediately following therapy with J5 antibody, and they demonstrated in vivo antibody localization to circulating and bone marrow tumor cells. Antimurine antibody responses were not described; however, resistance to therapy was mediated in part by antigenic modulation of CALLA (loss of antigen from the cell surface membrane) in response to treatment with J5 antibody.
A series of IgM monoclonal antibodies recognizing glycolipid determinants on acute myelogenous leukemia (AML) cells and an IgG2b antibody recognizing a protein on the surface membrane of AML cells were studied in a therapy trial of 3 patients (49) . Transient declines in circulating AML cells were reported with evidence of in vivo binding to circulating leukemia cells. No antigenic modulation was demonstrated with any of these antibodies. Human antimurine antibody responses were demonstrated in one of three patients. Toxicity was limited to mild fever, back pain, arthralgia, and myalgia.
We have recently completed a Phase I trial with escalating doses of the antimelanoma monoclonal antibody 9.2.27 which recognizes a 250-kd glycoprotein/proteoglycan complex (53) . Doses from 1 to 500 mg were administered intravenously to patients with disseminated melanoma. Biopsies of skin nodules were taken prior to treatment to confirm the presence of the antigen recognized by 9.2.27. Subsequent biopsies were taken after intravenous administration of 9.2.27 to evaluate the presence of antibody binding in vivo on the tumor cells. Antibody binding in vivo could be demonstrated at doses above 10 rag, by either flow cytometry or immunoperoxidase techniques. Doses between 200 and 500mg were required to saturate all of the antigenic sites on the tumor cells on each nodule. Excellent selectivity of in vivo localization was seen, with staining of the melanoma cells within the nodules and no staining of the surrounding non-melanoma tissues. Antimouse antibody responses were demonstrated in one third of the patients, but they did not detectably impair the ability of the antibody to localize on tumor cells.
Sears and co-workers (54, 55) have treated 20 patients with metastatic gastrointestinal malignancies with the 17-1A IgG~ monoclonal antibody. All but 2 patients received a single injection in a dose range of 15 to 1000 mg per patient. Mouse antibody circulated in the patients' blood for 2 to 50 days and was identified in tumor tissues within 1 week of administration. Three patients remained tumorfree 22, 13, and 10 months after monoclonal antibody therapy.
Houghton and co-workers have reported 3 of 12 partial responses in patients with melanoma treated with an IgG 3 antibody designated R24, which recognizes GD3 , a prominent ganglioside on the surface of melanoma cells (56) . Interestingly, this antibody is cytotoxic in vitro with human complement and human effector cells, and inflammatory reactions were observed around tumor sites in some of the patients treated with this antibody.
Toxicity
Toxicities associated with monoclonal antibody therapy are generally quite mild. Fevers, chills, and urticaria are quite common but are not treatmentlimiting toxicities. Rare patients have developed shortness of breath associated with the rapid infusion of monoclonal antibodies, but this was not seen when the antibodies were infused at <5 mg/h (39, 41, 44, 45) . Occasional patients have developed hypotension and tachycardia following the infusion of murine monoclonal antibodies (39) (40) (41) . A limited number of patients have developed transient reduction in their creatinine clearance and elevation of their liver enzymes (42, 48) , thought to be secondary to immune complexes between monoclonal antibody and circulating antigen. In conclusion, murine-derived monoclonal antibodies can be safely infused; although side effects can be expected and are usually mild.
Anti-idiotype antibodies
Anti-idiotype monoclonal antibodies differ from other types of antibodies in that they are tumorspecific in the case of B cell derived tumor cells. Immunoglobulin molecules have a unique region in their variable region termed the 'idiotype', and the idiotype for every immunoglobulin molecule is different. Since B cell diseases are clonal diseases, each tumor cell expresses the same immunoglobulin molecule; therefore, the idiotype is identical on every tumor cell. In this unique situation, the idiotype is, therefore, a 'tumor-specific' antigen. A group of investigators from Stanford developed a monoclonal antibody to the idiotypic determinant from a patient with B cell lymphoma who had become resistant to cytotoxic drugs and interferon (57) . The patient had a complete and durable (>3 years) response to anti-idiotype antibody therapy (43) . An additional 8 patients with non-Hodgkin's lymphoma treated at Stanford and one with chronic lymphocytic leukemia treated at the National Cancer Institute have had only partial remissions or no responses at all. While anti-idiotype antibody therapy represents the most specific approach to monoclonal antibody therapy for B cell derived cancer, there are a number of problems. Generating anti-idiotype antibodies is labor intensive and is not practical on a large scale. Hopefully, this process can be refined as new techniques to develop these antibodies are developed. In addition, anti-idiotype antibodies are patient specific and, therefore, can be used to treat only a single patient. Two additional problems have recently been identified and will limit the therapeutic role for anti-idiotype antibody therapy. First, some tumors are biclonal and would require more than one antibody for successful therapy (58, 59) . Second, the idiotype may be unstable on some patients' tumor cells, probably because of somatic mutation within the variable region gene (60, 61) .
Problems in antibody therapy
There are additional obstacles to successful antibody therapy that are common to all murine-derived monoclonal antibodies. 'Antigenic modulation' is the loss of antigen from the cell surface membrane and occurs within minutes or hours after exposure to antibody. During the time that the cells are modulated, they no longer bind to antibody. The modulated cells will usually reexpress the antigen within 24 to 48 hours after the antibody infusion has been completed (when residual antibody is no longer in the serum). While modulation may be a problem for therapy with unconjugated free antibody, it may have a positive effect on immunoconjugate therapy. The antitumor effect of immunoconjugates may be greater when there is internal modulation of the immunoconjugate-antigen complex, which has been demonstrated to take place in a number of systems (62, 63) .
Murine-derived monoclonal antibodies can also stimulate the development of human antibodies to the murine immunoglobulin. This has been a limiting factor in some of the therapies with monoclonal antibodies, particularly in patients who are immunologically intact (64) . This problem might be overcome by using low-dose cytotoxic agents with the initial antibody infusion to destroy these antibody-producing clones. Human derived monoclonal antibodies would eliminate this problem, although responses to the idiotype or allotype of human immunoglobulin would still be possible. Finally, infusing high doses of antibody (>400 mg) at the onset of therapy might induce tolerance (55) .
Another problem with some antibody-tumor systems is tumor heterogeneity, with only a portion of the tumor cells reacting with a single antibody. This might be overcome by using multiple monoclonal antibodies to treat such a tumor.
Finally, monoclonal antibodies do not appear to be very effective in eliminating the tumor cells by themselves. Preclinical animal models suggest that antibodies conjugated to drugs, toxins, and radioisotopes are more cytotoxic and capable of far greater antitumor effects (65, 66) . This is a major direction of current research.
Bone marrow clean up
Another attractive therapeutic application of monoclonal antibodies is to 'clean up' autologous bone marrow prior to bone marrow transplantation. Patients who are in clinical remission will often have morphologically undetectable tumor cells in their bone marrow which theoretically could be detected and destroyed with specific antibodies and complement (or antibodies conjugated to toxins). Most of the obstacles and toxicities with monoclonal antibody infusion would be eliminated using this technology. Such an approach has been reported using B1 monoclonal antibody to clean up autologous bone marrow from patients with nonHodgkin's lymphoma (67) . Eight patients who had relapsed with B cell non-Hodgkin's lymphoma were first induced into a minimum disease state (with <5% bone marrow involvement with tumor). Bone marrow was then removed and treated with anti-B1 antibody and complement. Patients were then treated with intensive chemoradiotherapy and were reconstituted with anti-B1 treated autologous bone marrow. All patients achieved a complete clinical response and engrafted by 8 weeks. There was no significant toxicity; B cells were detected by 2 months after transplantation and normal immunoglobulin levels were achieved by 6 months. Six of 8 patients were disease free in unmaintained remission for 3 to 20 months after transplantation. Similar results have been reported for the J5 antibody and patients with acute lymphoblastic leukemia (68) . Results of Biological therapy of cancer 11 these trials are preliminary but have clearly demonstrated that antibody-treated autologous bone marrow is capable of restoring hematopoiesis. Long-term disease-free survival will be necessary before concluding that these therapies have been successful.
Conclusions
Interferons have shown activity in a number of hematologic malignancies, even in previously treated patients; Phase III trials with untreated patients appear justified. Responses to interferons in most solid tumors, however, have been limited in preliminary trials. The use of monoclonal antibody immunoconjugates in the treatment of cancer is in its infancy. While much work needs to be done to clarify many of the issues surrounding the use of monoclonal antibodies, it has been clearly demonstrated in both animal tumor models and humans that both antibodies alone and antibody conjugates can be safely administered with minimal adverse effects and, in selected cases, can have therapeutic value.
Problems such as antigenic modulation, host antibody response, and antigenic heterogeneity are all major obstacles to safe and effective therapy with monoclonal antibodies. These issues are under investigation in animal models and humans.
While anti-idiotype antibodies are highly specific and have demonstrated excellent responses in a small number of patients, problems such as biclonality of some lymphomas, instability of the idiotype, and the difficulty of making 'tailor-made' antibodies for individual patients clearly limit the role of anti-idiotype therapy.
Purging of bone marrow with antibodies and complement (or coupled to toxins) is limited to only a few diseases. However, studies thus far have demonstrated that tumor cells can be removed from the bone marrow by in vitro treatment with antibody and complement, and that this treated bone marrow can successfully engraft; a number of patients have been rendered disease-free for over one year. This may prove to be an important application of monoclonal antibody therapy, and it by-passes most of the problems with monoclonal antibody infusion therapy described above.
Perhaps the most important future role for monoclonal antibody therapy will be in patients with minimal disease in the 'adjuvant' setting, where immunoconjugates may localize and destroy micrometastatic deposits of tumor cells. We remain cautiously optimistic in exploring these exciting new approaches to cancer therapy.
